Trial Profile
An Open Label Non Randomized Access Study of Trametinib for Patients With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Oct 2022
Price :
$35
*
At a glance
- Drugs Trametinib (Primary) ; Dabrafenib
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 25 Sep 2022 Results of subgroup analysis assessing efficacy in patients with BRAFV600-mutant melanoma and BM treated with BRAF and MEK inhibitors dabrafenib and trametinib, published in the European Journal of Cancer
- 06 Jul 2021 Results of an analysis assessing the safety, response to treatment, progression-free survival and factors associated with progression, and stratified the population into risk groups published in the European Journal of Cancer
- 14 May 2017 Status changed from recruiting to completed.